Search for a trial

LUME-Lung 3. A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology.

Run-in phase I: To confirm the safety and tolerability of BIBF 1120 up to a dose level of 200 mg b.i.d added to a standard dose of cisplatin/gemcitabine in first line NSCLC patients with squamous cell histology. Pharmacokinetics of BIBF 1120 and…

Genetic variations as predictors of outcome and toxicity in non-small-cell lung cancer patients undergoing chemoradiation or chemotherapy with platinum agents.

The objective of this study is to identify genetic variations associated with clinical response and toxicity in non-small cell lung cancer patients (NSCLC) undergoing chemoradiation or chemotherapy with platinum agents (carboplatin, cisplatin). The…

A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)

This study has been transitioned to CTIS with ID 2023-509137-39-00 check the CTIS register for the current data. Primary/dualco-primary. To prospectively investigate whether adjuvant treatment with pembrolizumab after completion of radical surgery (…

A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non Small Cell Lung Cancer

This study has been transitioned to CTIS with ID 2023-505057-40-00 check the CTIS register for the current data. This study is looking at how safe the combination of the experimental drugs dostarlimab, belrestotug and GSK6097608 is in patients with…